A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial

作者：Roviello Giandomenico; Milani Manuela; Gobbi Angela; Dester Martina; Cappelletti Maria Rosa; Allevi Giovanni; Aguggini Sergio; Ravelli Andrea; Gussago Francesca; Cocconi Alessandra; Zanotti Laura; Senti Chiara; Strina Carla; Bottini Alberto; Generali Daniele^*

来源：Future Oncology, 2016, 12(19): 2189-2193.

DOI：10.2217/fon-2016-0116

• BRCA
• olaparib
• triple-negative breast cancer

The OLTRE trial (ClinicalTrials.gov number: NCT02681562) is an open-label, 'window of opportunity' Phase II controlled trial to evaluate the biological activity of olaparib in locally advanced triple-negative breast cancer compared with other subtypes of locally advanced breast cancer patients carrying germinal BRCA mutation receiving olaparib with the same treatment approach. The primary end point is to investigate the correlation between baseline gene and protein expression profile in order to identify possible predictive markers of response to olaparib. The OLTRE trial is expected to identify the surrogate markers of the biological activity of olaparib in the treatment of patients with triple-negative breast cancer.

• 出版日期2016-10